It is manufactured in Denmark at the facility of Novo Nordisk
Severe gastrointestinal disease, particularly gastroparesis, may be exacerbated by semaglutide due to its effects on gastric emptying
Loomba R, Hartman ML, Lawitz EJ, Vuppalanchi R, Boursier J, Bugianesi E, et al
These can include: Digestive issues that could lead to dehydration and cause kidney damage Gastrointestinal issues like pancreatitis or gallbladder disease Low blood pressure Low blood sugar levels There is also a black box warning, the most serious kind from the FDA, on both medications for the risk of a certain rare type of thyroid cancer
Now semaglutide represents an innovative approach to weight loss medication one that treats obesity as a serious and complex metabolic disease requiring ongoing medical care